1051 – Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies

Abstract

Introduction Lurasidone has demonstrated efficacy treating adults with schizophrenia, the majority of them with chronic, multi-episode schizophrenia. Objective To assess baseline characteristics and evaluate efficacy of lurasidone in patients with early-stage schizophrenia (ESS). Aims Evaluate efficacy of lurasidone in patients with ESS. Methods A pooled analysis of patients with ESS (defined as onset of illness within 3 years of study entry) from three, 6-week, randomized, placebo-controlled, phase 3 trials was performed. Additional analysis was conducted for patients with onset within 5 years. Efficacy was evaluated using a mixed-model repeated-measures analysis of change in PANSS total score and CGISeverity score. Treatment response was defined as ≥20% improvement in PANSS total score from baseline. Results 857 subjects were randomized to lurasidone and 366 to placebo of which 102(11.9%) lurasidone and 44(12.0%) placebo subjects had ESS (onset within 3 years). Among 146 ESS subjects, 70.5% were male, mean age was 28.6 years. Baseline PANSS total and CGI-S scores were 96.8 and 5.0 respectively. Lurasidone treatment of early-stage schizophrenia subjects showed significant improvement vs placebo in PANSS total score (-25.9 vs -17.3; p Conclusion In this subgroup analysis, lurasidone was effective in the treatment of patients with early-stage schizophrenia.